Normal Pressure Hydrocephalus (NPH) in Elderly

Clinical Guide: Normal Pressure Hydrocephalus (NPH) in the Elderly

1. Comprehensive Introduction & Overview

Normal Pressure Hydrocephalus (NPH) represents a unique and often reversible form of dementia and gait disturbance in the elderly population. Unlike obstructive hydrocephalus, which presents with acute signs of increased intracranial pressure (ICP), NPH is characterized by chronic, communicating ventricular enlargement without a proportional elevation in opening pressure during lumbar puncture (LP).

Historically described by Hakim and Adams in 1965, NPH is defined by the classic "Hakim’s Triad": gait disturbance, urinary incontinence, and cognitive decline. Because these symptoms mirror common age-related conditions—such as Parkinson’s disease, Alzheimer’s disease, and benign prostatic hyperplasia—NPH is frequently underdiagnosed or misdiagnosed. As the global population ages, the clinical recognition of NPH has become a priority in geriatric neurology and neurosurgery, primarily because it is one of the few "treatable" causes of dementia.

2. Deep-Dive: Pathophysiology and Mechanisms

The pathophysiology of NPH remains a subject of intense investigation. While the exact trigger is often elusive, the underlying mechanism involves the disruption of Cerebrospinal Fluid (CSF) dynamics.

The Dynamics of CSF

CSF is produced by the choroid plexus, circulates through the ventricles into the subarachnoid space, and is reabsorbed by the arachnoid granulations. In NPH, the balance between production and absorption is perturbed, though the mechanism is not a simple obstruction.

• Reduced Compliance: Decreased intracranial compliance leads to increased pulse pressure within the ventricles.
• The "Two-Hit" Hypothesis: It is theorized that an initial insult (e.g., subarachnoid hemorrhage, meningitis, or trauma) leads to fibrosis of the arachnoid granulations, impairing absorption. A secondary "hit" (chronic ischemia or small vessel disease) then exacerbates the situation.
• Venous Outflow Obstruction: Recent studies suggest that impaired venous outflow from the cranium contributes to the "stagnation" of CSF, leading to ventricular enlargement.

Ventricular Enlargement

The hallmark of NPH is ventriculomegaly. Crucially, the ventricles enlarge out of proportion to the degree of cerebral atrophy. This is quantified by the Evans Index (the ratio of the maximum width of the frontal horns of the lateral ventricles to the maximum internal diameter of the skull). An index >0.3 is highly suggestive of NPH.

3. Clinical Indications & Diagnostic Staging

NPH is categorized into two primary types:
1. Idiopathic NPH (iNPH): No identifiable cause; typically occurs in patients aged 60+.
2. Secondary NPH: Occurs after a known insult (trauma, hemorrhage, infection).

The Clinical Triad (Hakim’s Triad)

The progression usually follows a specific sequence, though not every patient presents with all three symptoms initially.

Diagnostic Staging (Stein and Langfitt Criteria)

Clinical grading helps determine candidacy for surgical intervention (Ventriculoperitoneal Shunting):
* Stage I (Mild): Minimal gait disturbance; no cognitive deficit.
* Stage II (Moderate): Clear gait issues; mild cognitive impairment; occasional urgency.
* Stage III (Severe): Wheelchair-bound; dementia; total incontinence.

4. Diagnostic Testing Protocols

To differentiate NPH from neurodegenerative diseases like Alzheimer’s, a multi-modal diagnostic approach is required.

Imaging

• MRI (Brain): The gold standard. Look for disproportionately enlarged subarachnoid space hydrocephalus (DESH). This features enlarged ventricles, narrowed sulci at the vertex, and widened Sylvian fissures.
• CT (Brain): Useful for initial screening to calculate the Evans Index and rule out structural lesions.

CSF Dynamic Studies

• Large-Volume Lumbar Puncture (LVLP): The "Tap Test." Removal of 30–50 mL of CSF. If gait improves significantly within hours to days, the patient is an excellent candidate for shunting.
• External Lumbar Drainage (ELD): A 3-day continuous drainage protocol. More sensitive than a single tap test.
• Infusion Manometric Testing: Measuring the resistance to CSF outflow ($R_{out}$). High resistance indicates poor absorption.

5. Differential Diagnosis: Avoiding Misdiagnosis

NPH is frequently misdiagnosed due to overlapping symptoms with other geriatric pathologies.

6. Surgical Intervention and Long-Term Prognosis

The definitive treatment for NPH is the placement of a Ventriculoperitoneal (VP) Shunt.

• Procedure: A catheter is inserted into the lateral ventricle, connected to a programmable valve, and tunneled to the peritoneal cavity to divert excess CSF.
• Programmable Valves: Allow neurosurgeons to adjust the pressure threshold non-invasively after surgery to optimize CSF flow.
• Success Rates: Patients with the "classic triad" and a positive response to the Tap Test have a 70–90% chance of significant symptom improvement.
• Prognosis: Gait disturbances show the highest rate of recovery. Cognitive symptoms are often slower to improve and may not fully resolve if cortical damage has already occurred.

Risks and Complications

• Shunt Infection: 2–5% risk; requires replacement and antibiotics.
• Shunt Malfunction: Obstruction or migration of the catheter.
• Subdural Hematoma: Rapid over-drainage of CSF can cause the brain to pull away from the dura, tearing bridging veins.
• Over-drainage/Under-drainage: Requires clinical monitoring and valve pressure adjustments.

7. Massive FAQ Section

1. Is NPH the same as "water on the brain"?
Technically, yes, but specifically, it is a chronic, non-acute form of hydrocephalus where the pressure remains within the "normal" range during standard measurements.

2. Can NPH be cured?
It is one of the few reversible forms of dementia. While surgical shunting is highly effective, "cure" depends on how early the diagnosis is made before permanent brain damage occurs.

3. What is the "Magnetic Gait"?
It describes a gait where the patient’s feet seem glued to the floor, making it difficult to initiate a step. It is a hallmark of NPH.

4. Why is the Tap Test so important?
It serves as a "test drive." If the patient’s gait improves after removing 30-50mL of CSF, it provides high confidence that a permanent shunt will also be successful.

5. What is the Evans Index?
It is a radiological calculation. If the lateral ventricles are wider than 30% of the maximum internal skull diameter, it supports the diagnosis of ventriculomegaly.

6. Does NPH cause memory loss?
NPH usually causes "executive dysfunction" (trouble planning, organizing, and focusing) rather than the classic short-term memory loss associated with Alzheimer’s.

7. Can an elderly person be too old for surgery?
Age alone is not a contraindication. If the patient has a reasonable life expectancy and the diagnosis is confirmed, the benefits of regaining mobility often outweigh the surgical risks.

8. What happens if NPH is left untreated?
The symptoms progress. Gait disturbance leads to falls, followed by complete immobility, incontinence, and profound dementia.

9. Are there non-surgical treatments?
No. Pharmacological treatments (like acetazolamide) are generally ineffective for long-term management of NPH. Surgery is the only definitive intervention.

10. How often do I need to see a specialist after a shunt?
Post-operative follow-up is critical. Usually, patients are seen at 1 month, 3 months, 6 months, and then annually to adjust the valve pressure and assess neurological status.

8. Clinical Conclusion

Normal Pressure Hydrocephalus is a critical diagnosis in the geriatric population. Due to the potential for significant clinical improvement, a high index of suspicion is required. Clinicians should be wary of labeling "gait, cognition, and incontinence" as merely "aging." By utilizing the Evans Index, MRI/CT imaging, and the Lumbar Tap Test, physicians can identify candidates for shunt surgery, potentially restoring quality of life and preventing permanent neurological morbidity. Early identification remains the single most important factor in the success of the clinical pathway.